UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington's Data Spurs Mizuho Downgrade and Delayed Launch [Yahoo! Finance]
uniQure N.V. - Ordinary Shares (QURE)
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
uniqure.com/investors-newsroom/overview.php
Company Research
Source: Yahoo! Finance
uniQure to $33 from $60, while keeping an Outperform rating on the shares. The firm adjusted its financial model for AMT-130 after the company announced that the FDA communicated concerns that the current data submitted from the Phase I/II studies for Huntington's disease are presently unlikely to serve as the primary evidence needed to support a BLA. Consequently, Mizuho reduced its view of AMT-130's probability of success and delayed its expected launch by 1 year. In other news, earlier in its Q3 2025 earnings report, UniQure detailed promising clinical data for its lead gene therapy candidate, AMT-130, alongside new regulatory challenges. The company reported $3.7 million in revenue, an increase from $2.3 million in Q3 2024. However, financial expenses rose, with R&D expenses reaching $34.4 million (up from $30.6 million in Q3 2024) and SG&A expenses totaling $19.4 million (up from $11.6 million in Q3 2024). The increase in R&D was primarily driven by costs associated with prepar
Show less
Read more
Impact Snapshot
Event Time:
QURE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QURE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QURE alerts
High impacting uniQure N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
QURE
News
- QURE INVESTIGATION: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the FirmGlobeNewswire
- uniQure (NASDAQ:QURE) had its price target lowered by analysts at Stifel Nicolaus from $50.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the FirmPR Newswire
- uniQure (NASDAQ:QURE) was given a new $33.00 price target on by analysts at Mizuho.MarketBeat
- Notice of Investigation of QURE: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the FirmGlobeNewswire
QURE
Earnings
- 11/10/25 - Miss
QURE
Sec Filings
- 12/4/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- QURE's page on the SEC website